ABSTRACT
The working experience of the Moscow oblast center for multiple sclerosis is analyzed. Along with standard methods of treatment efficacy evaluation, a cytokines (tumor necrosis factor alpha, gamma-interferon, interleukins 10 and 17) measurement, a morphological study of CD4 and CD8 lymphocytes with cell microelectrophoresis, a complex of morphometric and optic cell parameters using laser computed phase-interference microscopy and cell optic coherent tomography of the eye's retina are used. Preliminary results of the efficacy of these methods are presented.
Subject(s)
Cytokines/blood , Interferon-beta/therapeutic use , Multiple Sclerosis/drug therapy , Peptides/therapeutic use , Propylene Glycols/therapeutic use , Sphingosine/analogs & derivatives , Brain/pathology , Drug Therapy, Combination , Fingolimod Hydrochloride , Follow-Up Studies , Glatiramer Acetate , Humans , Immunologic Factors/therapeutic use , Immunosuppressive Agents/therapeutic use , Magnetic Resonance Imaging , Multiple Sclerosis/blood , Multiple Sclerosis/diagnosis , Secondary Prevention , Sphingosine/therapeutic use , Time Factors , Treatment OutcomeABSTRACT
We present the results of a one-year follow-up study of 11 patients treated with gilenya. The results of cardiomonitoring (ECG and daily arterial pressure monitoring) during the treatment with the first dose of the drug are presented. No clinically significant disturbances of functions in patients without cardiovascular diseases were noted. In these cases, no progression of disease was identified. Relapses were not observed in 82% of patients.
